NCT05362955View on ClinicalTrials.gov

5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
CIN 2/3HIV Infections
Interventions
DRUG

Intravaginal 5-Fluorouracil (5-FU)

Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.

Trial Locations (1)

614-40100

Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building, Kisumu

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER